Sorry, it's was for me. Thanks for the question. I was on mute.
I think I'll address the first question later on, if we have time, but to the second question about monoclonal antibodies, I'll say a few things in response.
I sit on and chair Ontario's scientific advisory table. Even though much of the country looks to our table for advice, it's Ontario's scientific advisory table. We mainly provide advice on therapies that are currently available to Canadians. The only monoclonal antibody that is available to Canadians at present is bamlanivimab. As you pointed out, there are problems with bamlanivimab monotherapy, and they continue. They're not just theoretical. They were demonstrated in the trials, especially in BLAZE-1, where there was an emergence of antibody-resistant variants while on therapy. Because of that, I would strongly suggest that we not use bamlanivimab.
I see that my time is up, Mr. Chair. I don't know if you want me to finish the rest of the question.